---
title: Poliomyelitis Virus Type 1
description: >-
  Poliomyelitis Virus Type 1 is a component of vaccines used for active
  immunization against poliomyelitis. It is not a drug, but a crucial part of
  vaccines designed to prevent polio infection.  The pharmacological
  classification of the vaccine containing this viral component is *vaccine*,
  specific...
is_banned: false
lastModified: '2025-09-22T17:21:53.937Z'
faqs:
  - q: >-
      What is the recommended dosage for Poliomyelitis Virus Type 1 vaccine
      (IPV)?**


      **A:**  Refer to the detailed dosage guidelines above, which cover adult,
      pediatric, and special populations.
    a: >-
      A:**  Refer to the detailed dosage guidelines above, which cover adult,
      pediatric, and special populations.
  - q: >-
      Can IPV be given to immunocompromised individuals?**


      **A:** Yes, IPV can generally be administered to immunocompromised
      individuals, as it contains inactivated virus. However, individual
      clinical evaluation is essential.
    a: >-
      A:** Yes, IPV can generally be administered to immunocompromised
      individuals, as it contains inactivated virus. However, individual
      clinical evaluation is essential.
  - q: |-
      Are there any long-term side effects of IPV?**

      **A:** No significant long-term side effects of IPV have been documented.
    a: 'A:** No significant long-term side effects of IPV have been documented.'
  - q: >-
      Can IPV be given with other vaccines?**


      **A:** Yes, IPV can be administered concurrently with other vaccines,
      often in combination formulations.
    a: >-
      A:** Yes, IPV can be administered concurrently with other vaccines, often
      in combination formulations.
  - q: >-
      What are the signs of an allergic reaction to IPV?**


      **A:** Signs of an allergic reaction may include hives, swelling of the
      face, lips, or tongue, difficulty breathing, dizziness, and/or a rapid
      heartbeat. Immediate medical attention is required if these occur.
    a: >-
      A:** Signs of an allergic reaction may include hives, swelling of the
      face, lips, or tongue, difficulty breathing, dizziness, and/or a rapid
      heartbeat. Immediate medical attention is required if these occur.
  - q: >-
      How effective is IPV?**


      **A:** IPV is highly effective, providing protection against all three
      types of poliovirus in almost all vaccinated individuals after the
      completion of the primary series.
    a: >-
      A:** IPV is highly effective, providing protection against all three types
      of poliovirus in almost all vaccinated individuals after the completion of
      the primary series.
  - q: |-
      Is IPV safe for pregnant women?**

      **A:**  Yes, IPV is considered safe to administer during pregnancy.
    a: 'A:**  Yes, IPV is considered safe to administer during pregnancy.'
  - q: >-
      Can IPV cure polio?**


      **A:** No, IPV is a preventative measure. It cannot cure polio infection,
      but it can prevent its development if administered prior to exposure.
    a: >-
      A:** No, IPV is a preventative measure. It cannot cure polio infection,
      but it can prevent its development if administered prior to exposure.
  - q: >-
      What if a dose of IPV is missed?**


      **A:** If a dose is missed, consult the latest catch-up vaccination
      schedules provided by relevant health authorities (e.g., CDC, WHO,
      National immunization programs).


      As of today, February 17, 2025, this information is current, however,
      medical knowledge and guidelines are subject to ongoing updates.  Always
      consult the latest authoritative resources for the most recent
      recommendations.
    a: >-
      A:** If a dose is missed, consult the latest catch-up vaccination
      schedules provided by relevant health authorities (e.g., CDC, WHO,
      National immunization programs).


      As of today, February 17, 2025, this information is current, however,
      medical knowledge and guidelines are subject to ongoing updates.  Always
      consult the latest authoritative resources for the most recent
      recommendations.
---
## **Usage**

Poliomyelitis Virus Type 1 is a component of vaccines used for active immunization against poliomyelitis. It is not a drug, but a crucial part of vaccines designed to prevent polio infection.  The pharmacological classification of the vaccine containing this viral component is *vaccine*, specifically a *viral vaccine*.  The inactivated polio vaccine (IPV) works by introducing inactivated (killed) poliovirus types 1, 2, and 3 into the body. This prompts an immune response, leading to the production of antibodies against all three types of poliovirus, without causing the disease. These antibodies provide long-term protection against poliomyelitis.


## **Alternate Names**

The inactivated virus itself might be referred to as inactivated poliovirus type 1, or simply poliovirus type 1 (inactivated). In the context of vaccines, the whole inactivated vaccine may be referred to as IPV. Some brand names for vaccines containing inactivated poliovirus type 1 include IPOL, and it's also a component of various combination vaccines like Pentacel, Pediarix, Kinrix, Quadracel, and VAXELIS.


## **How It Works**

### **Pharmacodynamics**

IPV, containing the inactivated Poliomyelitis Virus Type 1, stimulates the body's immune system to produce specific antibodies against the virus.  This immune response targets the viral capsid proteins, effectively neutralizing the virus and preventing its replication within the body.

### **Pharmacokinetics**

IPV is administered intramuscularly (IM) or subcutaneously (SC). The inactivated virus does not replicate. The antigen components of the vaccine are processed by antigen-presenting cells, which then stimulate B-lymphocytes to produce specific antibodies. The pharmacokinetics of IPV, regarding absorption, distribution, metabolism, and excretion, primarily pertain to the clearance of the inactivated viral particles and other vaccine components from the injection site and their subsequent elimination from the body. More detailed pharmacokinetic studies related to the individual vaccine components and the duration of antibody responses may be available in specific vaccine literature.


## **Dosage**


### **Standard Dosage**

#### **Adults (Unvaccinated or Incompletely Vaccinated):**

* **Primary Series:**  Three doses of IPV (0.5 mL each) are recommended.
    * Two doses administered 1-2 months apart.
    * A third dose administered 6-12 months after the second dose.

* **Booster Dose (for those at increased risk):** A single lifetime booster dose of IPV is recommended for adults at increased risk of exposure to poliovirus (e.g., travelers to endemic regions, laboratory workers handling poliovirus).  This booster is typically given years after the primary series, but the exact interval is not universally defined, it's usually guided by the context of exposure risk and local/national health guidelines.

#### **Children:**

* **Primary Series:** Four doses of IPV (0.5 mL each) are recommended as part of routine childhood immunization at ages 2 months, 4 months, 6-18 months, and 4-6 years.
* When combination vaccines are used, an additional (fifth) dose of IPV may be given as part of the childhood vaccination series.

#### **Special Cases:**

* **Elderly Patients:** Same dosage as adults.
* **Patients with Renal/Hepatic Impairment:** Dose adjustments are not typically required for IPV.
* **Patients with Comorbid Conditions:**  No specific dose modifications for IPV are generally recommended.  However, individual clinical judgement is always paramount.


### **Clinical Use Cases**

IPV is used for *prevention* of polio and is not indicated for treatment or management during situations like intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations.  In these cases, supportive care and management of complications are crucial.


## **Side Effects**


### **Common Side Effects:**

* Soreness, redness, or swelling at the injection site.
* Mild fever.



### **Rare but Serious Side Effects:**

Allergic reactions (e.g., hives, swelling of the face, difficulty breathing) are rare but require immediate medical attention.


## **Contraindications**

* Severe allergic reaction to a previous dose of IPV or any of its components.


## **Drug Interactions**

No specific clinically significant drug interactions have been consistently reported with IPV.  However, as a standard medical practice, inform the vaccinating physician of all medications the patient is currently taking.


## **Pregnancy and Breastfeeding**

IPV can be administered during pregnancy and breastfeeding.


## **Drug Profile Summary**

* **Mechanism of Action:** Stimulates antibody production against poliovirus types 1, 2, and 3.
* **Side Effects:** Generally mild and localized to the injection site.  Rare allergic reactions can occur.
* **Contraindications:** Severe allergic reaction to a previous dose or components.
* **Drug Interactions:**  No major clinically significant interactions.  
* **Pregnancy & Breastfeeding:**  Safe to administer.
* **Dosage:** See detailed dosage guidelines above.
* **Monitoring Parameters:**  Observe patient for any signs of allergic reactions post-vaccination.  Routine antibody titre monitoring isn't usually recommended.


## **Popular Combinations**

IPV is often included in combination vaccines with diphtheria, tetanus, pertussis, hepatitis B, and *Haemophilus influenzae* type b components. This allows for efficient immunization against multiple diseases simultaneously.


## **Precautions**

Standard aseptic techniques should be followed during administration. Patients should be observed briefly post-vaccination for any immediate adverse reactions.  Any history of allergies should be thoroughly evaluated before administering IPV.


## **FAQs (Frequently Asked Questions)**


### **Q1: What is the recommended dosage for Poliomyelitis Virus Type 1 vaccine (IPV)?**

**A:**  Refer to the detailed dosage guidelines above, which cover adult, pediatric, and special populations.

### **Q2: Can IPV be given to immunocompromised individuals?**

**A:** Yes, IPV can generally be administered to immunocompromised individuals, as it contains inactivated virus. However, individual clinical evaluation is essential.

### **Q3: Are there any long-term side effects of IPV?**

**A:** No significant long-term side effects of IPV have been documented.

### **Q4: Can IPV be given with other vaccines?**

**A:** Yes, IPV can be administered concurrently with other vaccines, often in combination formulations.

### **Q5: What are the signs of an allergic reaction to IPV?**

**A:** Signs of an allergic reaction may include hives, swelling of the face, lips, or tongue, difficulty breathing, dizziness, and/or a rapid heartbeat. Immediate medical attention is required if these occur.

### **Q6: How effective is IPV?**

**A:** IPV is highly effective, providing protection against all three types of poliovirus in almost all vaccinated individuals after the completion of the primary series.

### **Q7: Is IPV safe for pregnant women?**

**A:**  Yes, IPV is considered safe to administer during pregnancy.

### **Q8: Can IPV cure polio?**

**A:** No, IPV is a preventative measure. It cannot cure polio infection, but it can prevent its development if administered prior to exposure.

### **Q9: What if a dose of IPV is missed?**

**A:** If a dose is missed, consult the latest catch-up vaccination schedules provided by relevant health authorities (e.g., CDC, WHO, National immunization programs).

As of today, February 17, 2025, this information is current, however, medical knowledge and guidelines are subject to ongoing updates.  Always consult the latest authoritative resources for the most recent recommendations.
